Pleomorphic lobular carcinoma in situ of the breast: Clinicopathological review of 47 cases

Histopathology

Volumn 64, Issue 7, 2014, Pages 981-993

  Khoury, Thaer ^a   Karabakhtsian, Rouzan G ^b   Mattson, David ^a   Yan, Li ^a   Syriac, Susanna ^a   Habib, Fadi ^a   Liu, Song ^a   Desouki, Mohamed M ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; Breast; Local recurrence; Pleomorphic lobular carcinoma in situ

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; UVOMORULIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL FEATURE; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; PATIENT RISK; PLEOMORPHIC ADENOMA; PLEOMORPHIC LOBULAR CARCINOMA IN SITU; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; ADJUVANT CHEMOTHERAPY; BREAST; BREAST NEOPLASMS; CARCINOMA, LOBULAR; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK;

EID: 84899915163     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12353     Document Type: Article

References (26)

1. Lakhani SR, Schnitt SJ, O'Malley F, van de Vijver MJ, Simpson PT, Palacios J. Lobular neoplasia. In Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ eds. World Health Organization classification of tumors of the breast. 4th ed. Lyon: IARC, 2012; 78-80.
2. Menon S, Porter GJ, Evans AJ et al. The significance of lobular neoplasia on needle core biopsy of the breast. Virchows Arch. 2008; 452; 473-479.
3. Bratthauer GL, Tavassoli FA. Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Arch. 2002; 440; 134-138.
4. Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod. Pathol. 2002; 15; 1044-1050.
5. Blair SL, Emerson DK, Kulkarni S, Hwang ES, Malcarne V, Ollila DW. Breast surgeon's survey: no consensus for surgical treatment of pleomorphic lobular carcinoma in situ. Breast J. 2013; 19; 116-118.
6. Tavassoli FA, Eusebi MD. Tumors of the mammary gland, AFIP atlas of tumor pathology. Washington, DC: ARP Press, 2009; 53-67.
7. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999; 17; 1474-1481.
8. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch. Pathol. Lab. Med. 2007; 131; 18-43.
9. Zhao C, Desouki MM, Florea A, Mohammed K, Li X, Dabbs D. Pathologic findings of follow-up surgical excision for lobular neoplasia on breast core biopsy performed for calcification. Am. J. Clin. Pathol. 2012; 138; 72-78.
10. Rakha EA, Ellis IO. Lobular breast carcinoma and its variants. Semin. Diagn. Pathol. 2010; 27; 49-61.
11. Sullivan ME, Khan SA, Sullu Y, Schiller C, Susnik B. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. Arch. Pathol. Lab. Med. 2010; 134; 1024-1028.
12. Dabbs DJ, Schnitt SJ, Geyer FC et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am. J. Surg. Pathol. 2013; 37; e1-e11.
13. Georgian-Smith D, Lawton TJ. Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. AJR Am. J. Roentgenol. 2001; 176; 1255-1259.
14. Fadare O, Dadmanesh F, Alvarado-Cabrero I et al. Lobular intraepithelial neoplasia (lobular carcinoma in situ) with comedo-type necrosis: a clinicopathologic study of 18 cases. Am. J. Surg. Pathol. 2006; 30; 1445-1453.
15. Simpson PT, Reis-Filho JS, Lambros MB et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. Am. J. Surg. Pathol. 2008; 32; 773-783.
16. Chen YY, Hwang ES, Roy R et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am. J. Surg. Pathol. 2009; 33; 1683-1694.
17. Bagaria SP, Shamonki J, Kinnaird M, Ray PS, Giuliano AE. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma? Ann. Surg. Oncol. 2011; 18; 1845-1851.
18. Downs-Kelly E, Bell D, Perkins GH, Sneige N, Middleton LP. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch. Pathol. Lab. Med. 2011; 135; 737-743.
19. Fisher ER, Costantino J, Fisher B et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer 1996; 78; 1403-1416.
20. Stein LF, Zisman G, Rapelyea JA, Schwartz AM, Abell B, Brem RF. Lobular carcinoma in situ of the breast presenting as a mass. AJR Am. J. Roentgenol. 2005; 184; 1799-1801.
21. Haagensen CD, Lane N, Lattes R. Neoplastic proliferation of the epithelium of the mammary lobules: adenosis, lobular neoplasia, and small cell carcinoma. Surg. Clin. North Am. 1972; 52; 497-524.
22. Patchefsky AS, Schwartz GF, Finkelstein SD et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989; 63; 731-741.
23. Fisher B, Costantino JP, Wickerham DL et al. Moxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 2005; 97; 1652-1662.
24. Morrow M, Harris JR. Ductal carcinoma in situ and microinvasive carcinoma. In Harris JR, Lippman ME, Morrow M, Osborne CK eds. Disease of the breast. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins, 2004; 349-375.
25. Monhollen L, Morrison C, Ademuyiwa FO et al. Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type. Histopathology 2012; 61; 365-377.
26. Allred DC, Wu Y, Mao S et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin. Cancer Res. 2008; 14; 370-378.